Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.

Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R, Slaby O.

Biomed Res Int. 2015;2015:941980. doi: 10.1155/2015/941980. Epub 2015 May 3.

2.

Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus.

Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Svoboda M, Sachlova M, Slaby O.

Diagn Pathol. 2015 Apr 28;10:42. doi: 10.1186/s13000-015-0280-6.

3.

MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.

Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova J, Kren L, Hermanova M, Lenz J, Karasek P, Vyzula R, Slaby O.

Diagn Pathol. 2015 Apr 24;10:38. doi: 10.1186/s13000-015-0272-6.

4.

Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.

Slaby O, Srovnal J, Radova L, Gregar J, Juracek J, Luzna P, Svoboda M, Hajduch M, Ehrmann J.

Carcinogenesis. 2015 May;36(5):521-7. doi: 10.1093/carcin/bgv023. Epub 2015 Mar 16.

PMID:
25784377
5.

Small nucleolar RNAs functioning and potential roles in cancer.

Thorenoor N, Slaby O.

Tumour Biol. 2015 Jan;36(1):41-53. doi: 10.1007/s13277-014-2818-8. Epub 2014 Nov 25. Review.

PMID:
25420907
6.

Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.

Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M, Besse A, Nekvindova J, Hermanova M, Jancalek R, Svoboda M, Hajduch M, Slampa P, Vyzula R, Slaby O.

Carcinogenesis. 2014 Dec;35(12):2756-62. doi: 10.1093/carcin/bgu212. Epub 2014 Oct 16.

PMID:
25322872
7.

Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology.

Mlcochova H, Hezova R, Meli AC, Slaby O.

Methods Mol Biol. 2015;1218:439-63. doi: 10.1007/978-1-4939-1538-5_26. Review.

PMID:
25319667
8.

[The role of MicroRNAs in the pathophysiology of neuroblastoma and their possible use in diagnosis, prognosis and therapy].

Vinklárek J, Novák J, Bienertová-Vašků J, Stěrba J, Slabý O.

Klin Onkol. 2014;27(5):331-9. Review. Czech.

PMID:
25312710
9.

MicroRNA profiling of activated and tolerogenic human dendritic cells.

Stumpfova Z, Hezova R, Meli AC, Slaby O, Michalek J.

Mediators Inflamm. 2014;2014:259689. doi: 10.1155/2014/259689. Epub 2014 Apr 1.

10.

[The role of microRNAs in molecular pathology of esophageal cancer and their potential usage in clinical oncology].

Kovaříková A, Héžová R, Srovnal J, Rédová-Lojová M, Slabý O.

Klin Onkol. 2014;27(2):87-96. Review. Czech.

PMID:
24739044
11.

MicroRNA-206: a promising theranostic marker.

Novák J, Kružliak P, Bienertová-Vašků J, Slabý O, Novák M.

Theranostics. 2014 Jan 2;4(2):119-33. doi: 10.7150/thno.7552. eCollection 2014. Review.

12.

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.

Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R.

Haematologica. 2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500. Epub 2013 Nov 15.

13.

Urine microRNAs as potential noninvasive biomarkers in urologic cancers.

Mlcochova H, Hezova R, Stanik M, Slaby O.

Urol Oncol. 2014 Jan;32(1):41.e1-9. doi: 10.1016/j.urolonc.2013.04.011. Epub 2013 Sep 10. Review.

PMID:
24035473
14.

MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1615-24. doi: 10.1007/s00432-013-1470-9. Epub 2013 Jul 2. Review.

PMID:
23817698
15.

MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis.

Novák J, Vinklárek J, Bienertová-Vašků J, Slabý O.

Pediatr Blood Cancer. 2013 Nov;60(11):1739-46. doi: 10.1002/pbc.24664. Epub 2013 Jun 27. Review. Erratum in: Pediatr Blood Cancer. 2014 Feb;61(2):390.

PMID:
23813576
16.

Extension of microRNA expression pattern associated with high-risk neuroblastoma.

Bienertova-Vasku J, Mazanek P, Hezova R, Curdova A, Nekvindova J, Kren L, Sterba J, Slaby O.

Tumour Biol. 2013 Aug;34(4):2315-9. doi: 10.1007/s13277-013-0777-0. Epub 2013 Jun 20.

PMID:
23784455
17.

[Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].

Poprach A, Lakomý R, Selingerová I, Dolečková B, Bílek O, Slabý O, Héžová R, Fabian P, Staník M, Pavlík T, Bortlíček Z, Mlčochová H, Tkáč D, Vyzula R, Kiss I, Kocák I, Kocáková I, Svoboda M.

Klin Onkol. 2013;26(2):114-23. Czech.

PMID:
23718670
18.

The role of microRNAs in mitochondria in cancer.

Bienertova-Vasku J, Sana J, Slaby O.

Cancer Lett. 2013 Aug 9;336(1):1-7. doi: 10.1016/j.canlet.2013.05.001. Epub 2013 May 9. Review.

PMID:
23665507
19.

MicroRNAs involved in chemo- and radioresistance of high-grade gliomas.

Besse A, Sana J, Fadrus P, Slaby O.

Tumour Biol. 2013 Aug;34(4):1969-78. doi: 10.1007/s13277-013-0772-5. Epub 2013 Apr 9. Review.

PMID:
23568705
20.

Circulating miRNAs as new blood-based biomarkers for solid cancers.

Redova M, Sana J, Slaby O.

Future Oncol. 2013 Mar;9(3):387-402. doi: 10.2217/fon.12.192. Review.

PMID:
23469974
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk